CN110710690A - Prebiotic composition for rapid proliferation of beneficial intestinal bacteria - Google Patents
Prebiotic composition for rapid proliferation of beneficial intestinal bacteria Download PDFInfo
- Publication number
- CN110710690A CN110710690A CN201810762531.2A CN201810762531A CN110710690A CN 110710690 A CN110710690 A CN 110710690A CN 201810762531 A CN201810762531 A CN 201810762531A CN 110710690 A CN110710690 A CN 110710690A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- prebiotic composition
- prebiotics
- oligosaccharide
- inulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 32
- 241000894006 Bacteria Species 0.000 title claims abstract description 22
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 18
- 230000035755 proliferation Effects 0.000 title abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 16
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 16
- 229940029339 inulin Drugs 0.000 claims abstract description 16
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 15
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 12
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 12
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 11
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 8
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 8
- 230000002062 proliferating effect Effects 0.000 claims abstract description 7
- 235000012343 cottonseed oil Nutrition 0.000 claims abstract description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- 244000005709 gut microbiome Species 0.000 claims description 2
- -1 raffinose oligosaccharide Chemical class 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- 239000006041 probiotic Substances 0.000 abstract description 18
- 235000018291 probiotics Nutrition 0.000 abstract description 18
- 241000282414 Homo sapiens Species 0.000 abstract description 12
- 244000005700 microbiome Species 0.000 abstract description 7
- 235000021391 short chain fatty acids Nutrition 0.000 abstract description 6
- 150000004666 short chain fatty acids Chemical class 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 3
- 210000003608 fece Anatomy 0.000 abstract description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 2
- 230000008855 peristalsis Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 244000052616 bacterial pathogen Species 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000007692 rcm medium Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a prebiotic composition for rapidly proliferating intestinal beneficial bacteria, which comprises inulin, galacto-oligosaccharide and isomalto-oligosaccharide. The invention also discloses another prebiotic composition for rapidly proliferating intestinal beneficial bacteria, which comprises stachyose, cottonseed oligosaccharide, oligomannose and isomaltooligosaccharide. The invention adopts the combination of various prebiotics and the combination with dietary fiber, different prebiotics have different characteristics, the proliferated probiotics are different, the intestinal flora is a complex system, and the combination of various prebiotics can more effectively promote the proliferation of the probiotics compared with the single prebiotics. The dietary fiber is not digested and absorbed by human body, has strong water absorption, and can soften feces and increase intestinal peristalsis. Meanwhile, the prebiotics and the dietary fibers can be fermented by intestinal microorganisms to generate short-chain fatty acids, and the short-chain fatty acids can be used as energy sources of intestinal epithelial cells to protect intestinal mucosa and have anti-inflammatory and anti-tumor effects.
Description
Technical Field
The invention belongs to the technical field of biological compositions, and particularly relates to a prebiotic composition for rapidly proliferating beneficial bacteria in intestinal tracts.
Background
Inhabitation of microorganisms in the human intestinal tract1000 in an amount of about 1014Ten times as many as (one) of the human body's cells
F, Ley RE, Sonnenburg JL, et al science,2005,307(5717): 1915-20). The microorganisms can attach to intestinal mucosa to form a barrier to prevent pathogenic bacteria from colonizing, secrete various enzymes to help nutrient substances such as saccharides and proteins to be digested and absorbed, and synthesize various vitamins necessary for human body. In addition, more and more studies have shown that intestinal microorganisms are closely related to the development and development of obesity, diabetes, immunity, etc. (Jiehangya, Yu Zuo, etc., Chinese Biol., 2017 (11): 1467-. Thus, humans are considered to be super organisms consisting of self-cells and symbiotic microflora in vivo (Tumbaugh PJ, Ley RE, Hamady M, et al, Nature,2007,18,449(7164): 804-10).
The intestinal microorganisms of human body are mainly bacteria, and can be divided into symbiotic bacteria, conditional pathogenic bacteria and pathogenic bacteria (Shaogaqing, report of medical research biology 2016, 29 (1): 16-20). The symbiotic bacteria are main bodies of intestinal flora, are mainly obligate anaerobes such as lactobacillus and bifidobacterium, and are symbiotic with human bodies mutually, can form barriers in the intestinal tract to inhibit the colonization of pathogenic bacteria, and promote the metabolism and absorption of nutrients by hosts. Conditional pathogenic bacteria, such as enterobacteria, enterococcus and the like, also exist in a certain amount in the intestinal tracts of healthy people, and do not cause harm to human bodies under normal conditions, but once the immunity of a host is reduced or the microenvironment of the intestinal tracts is changed, the conditional pathogenic bacteria can quickly proliferate or shift, and further the diseases are caused. Pathogenic bacteria such as salmonella are mainly ingested with food, generally cannot colonize in intestinal tracts for a long time, and can multiply in large quantities and generate toxins after entering a human body, so that the balance of intestinal flora and the health of the human body are damaged.
Under normal conditions, the intestinal flora is in a relatively stable state, and the intestinal flora and the host interact with each other, so that the balance of intestinal microecology is maintained, and the health of the intestinal tract and a human body is ensured. But diet change, taking antibiotics, operation, radiotherapy and chemotherapy and the like can cause the change and even imbalance of intestinal flora, thereby causing gastrointestinal discomfort and diseases. Diarrhea is a common complication after chemoradiotherapy in tumor patients, such as diarrhea of grade 1-4 after 5-fluorouracil chemotherapy with incidence rate of 50-80%, wherein severe diarrhea of grade 3-4 is 5-30% (Kombau S, Benson AB, Catalano R, et al, J Pan symptom Manage,2000,19(2): 118-29). Diarrhea affects not only the quality of life of the patient, but also the therapeutic effect and may even be life threatening. The diarrhea after radiotherapy and chemotherapy is accompanied by the change of the intestinal flora of the patient. Research shows that the intestinal flora structure of diarrhea patients is changed after chemotherapy, the total number and diversity of the flora are reduced, and the abundance of beneficial bacteria such as lactobacillus and bifidobacterium is obviously reduced (Stringer AM, Al-Dasoqi N, Bowen JM, et Al, Support Care Cancer,2013,21(7): 1843-52); manichan C and other researches find that the similarity of the intestinal flora of diarrhea people after radiotherapy and the intestinal flora of non-diarrhea people is relatively stable, and the similarity before and after radiotherapy is higher (Manichan C, Varela E, et al, Am J Gastroenterol,2008,103: 1754-61).
The supplement of probiotics and prebiotics is an important means for improving the intestinal flora and microenvironment and promoting the intestinal health. The probiotics refer to living microorganisms which are beneficial to a host when supplemented in a sufficient amount, such as lactobacillus, bifidobacterium and the like, and the supplemented probiotics are obtained by directly adding a large amount of exogenous live bacteria so as to increase the number of beneficial bacteria in intestinal tracts. Most of the prebiotics are functional polysaccharides which are not digested and absorbed by human body and can be utilized by probiotics, such as inulin, fructo-oligosaccharide, galacto-oligosaccharide, stachyose, etc. The supplement of prebiotics can promote the proliferation of indigenous probiotics in the intestinal tract, thereby increasing the quantity of the probiotics and improving the intestinal flora structure. Besides the proliferation of beneficial intestinal bacteria, the prebiotics can be metabolized and fermented with various dietary fibers by the beneficial intestinal bacteria to generate short-chain fatty acids such as acetic acid, propionic acid, butyric acid and the like, so that the pH value of the intestinal tract can be effectively reduced, and the proliferation of pathogenic bacteria can be inhibited. In addition, short chain fatty acids provide energy for the proliferation of intestinal cells, which is beneficial for maintaining the structural and functional integrity of the intestinal tract, and also has anti-inflammatory and anti-tumor effects (JavierFem < z., Sa lRedondo-Blanco, et al, J Funct Foods,2016,25: 511-.
Exogenous probiotic supplementation requires a certain amount of live bacteria, and has certain limitations on the storage environment and the use method of the product. In addition, the survival rate of the exogenous viable bacteria after passing through gastric acid is still to be further determined whether the exogenous viable bacteria can be effectively planted for a long time in the intestinal tract or how many bacteria can be planted. Compared with probiotics, the prebiotics are more stable, the product quality is more controllable, and the use is more convenient, so the prebiotics are more popular with consumers.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a prebiotic composition for rapidly proliferating beneficial intestinal bacteria.
The invention aims to provide a prebiotic composition for rapidly proliferating beneficial bacteria in intestinal tracts, which is realized by the following technical scheme:
prebiotic composition for rapidly proliferating intestinal beneficial bacteria comprises inulin, galacto-oligosaccharide and isomalto-oligosaccharide.
According to a preferred embodiment of the invention, the weight ratio of inulin to isomaltooligosaccharide is 1: 10-10: 1, the weight ratio of inulin to galacto-oligosaccharide is 1: 10-10: 1.
according to a preferred embodiment of the invention, further comprising dietary fibres.
According to a preferred embodiment of the invention, the dietary fibres are selected from resistant dextrins.
According to a preferred embodiment of the invention, prebiotics selected from fructo-oligosaccharides and/or xylo-oligosaccharides are also included.
Another object of the present invention is to provide another prebiotic composition for rapid propagation of beneficial intestinal bacteria, which is prepared by the following technical scheme:
prebiotic compositions for the rapid proliferation of beneficial gut bacteria include stachyose, raffinose oligosaccharides, oligomannose and isomaltooligosaccharides.
According to a preferred embodiment of the present invention, wherein the weight ratio of stachyose to cottonseed oligosaccharide is 1: 10-10: 1, the weight ratio of stachyose to oligomannose is 11: 1-20: 1 or 1: 20-1: 11, the weight ratio of stachyose to isomaltose hypgather is 1: 10-10: 1.
according to a preferred embodiment of the invention, further comprising dietary fibres.
According to a preferred embodiment of the invention, the dietary fibres are selected from resistant dextrins.
According to a preferred embodiment of the invention, one or more prebiotics selected from fructo-oligosaccharides, inulin or xylo-oligosaccharides are also included.
The invention adopts the combination of various prebiotics and the combination with dietary fiber, different prebiotics have different characteristics, the proliferated probiotics are different, the intestinal flora is a complex system, and the combination of various prebiotics can more effectively promote the proliferation of the probiotics compared with the single prebiotics. The dietary fiber is not digested and absorbed by human body, has strong water absorption, and can soften feces and increase intestinal peristalsis. Meanwhile, the prebiotics and the dietary fibers can be fermented by intestinal microorganisms to generate short-chain fatty acids, and the short-chain fatty acids can be used as energy sources of intestinal epithelial cells to protect intestinal mucosa and have anti-inflammatory and anti-tumor effects.
Detailed Description
The present invention will be further described with reference to the following specific examples. It should be understood that the following examples are illustrative only and are not intended to limit the scope of the present invention.
Example 1:
the prebiotic composition comprises the following components in parts by weight:
50 parts of inulin;
50 parts of fructo-oligosaccharide.
Example 2:
the prebiotic composition comprises the following components in parts by weight:
20 parts of inulin;
50 parts of isomaltose hypgather;
and 30 parts of galactooligosaccharide.
Example 3:
the prebiotic composition comprises the following components in parts by weight:
30 parts of inulin;
30 parts of isomaltooligosaccharide;
and 40 parts of galactooligosaccharide.
Example 4:
the prebiotic composition comprises the following components in parts by weight:
example 5:
the prebiotic composition comprises the following components in parts by weight:
50 parts of stachyose;
and 50 parts of inulin.
Example 6:
the prebiotic composition comprises the following components in parts by weight:
example 7:
the prebiotic composition comprises the following components in parts by weight:
example 8:
the prebiotic composition comprises the following components in parts by weight:
and (3) performance testing:
in order to determine the proliferation effect of the prebiotic composition of the invention on probiotics, the growth conditions of lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus reuteri, lactobacillus plantarum and bifidobacterium longum in culture media containing various prebiotics are examined. Lactobacillus was activated and cultured in MRS medium (JC De Man, M Rogosa, ME Sharpe.J.Appl.Bacteriol,1960,23(1): 130-. Bifidobacterium (Mao YH, Song AX, et al. CarbohydrylPolym.2018, 181: 368. sub.375) was cultured in RCM medium with activation, then inoculated with 2% inoculum size in RCM-P medium (glucose in RCM medium was replaced with equal amount of prebiotics) and RCM-N medium (glucose in RCM medium was removed), cultured at 37 ℃ for 16-48h, and OD600 was measured to determine the growth status of each probiotic. The results of the proliferation of probiotics with different prebiotics and prebiotic compositions are presented in table 1.
TABLE 1 proliferation of probiotics by different prebiotics and prebiotic compositions
+ indicates that MRS-P compared to MRS-N, RCM-P compared to RCM-N final OD600 is significantly different;
indicates that MRS-P compared to MRS-N, RCM-P compared to RCM-N does not differ significantly in final OD 600.
As can be seen from table 1, the first prebiotic composition (examples 2, 3, 4) and the second prebiotic composition (examples 6, 7, 8) with different compositions proliferated more species of probiotics than the single prebiotic, and all 5 probiotics had significant proliferation effect and were better than the combination of inulin and fructo-oligosaccharide (example 1) and stachyose and inulin (example 5).
The embodiments of the present invention have been described in detail, but the embodiments are merely examples, and the present invention is not limited to the embodiments described above. Any equivalent modifications and substitutions to those skilled in the art are also within the scope of the present invention. Accordingly, equivalent changes and modifications made without departing from the spirit and scope of the present invention should be covered by the present invention.
Claims (10)
1. The prebiotic composition for rapidly proliferating the beneficial intestinal bacteria is characterized by comprising inulin, galacto-oligosaccharide and isomalto-oligosaccharide.
2. Prebiotic composition according to claim 1 wherein the weight ratio of inulin to isomaltooligosaccharide is 1: 10-10: 1, the weight ratio of inulin to galacto-oligosaccharide is 1: 10-10: 1.
3. the prebiotic composition of claim 1, further comprising a dietary fiber.
4. Prebiotic composition according to claim 3, characterised in that the dietary fibre is selected from resistant dextrins.
5. Prebiotic composition according to claim 1 or 3, characterized in that it further comprises a prebiotic selected from fructo-oligosaccharide and/or xylo-oligosaccharide.
6. A prebiotic composition for the rapid propagation of beneficial gut bacteria comprising stachyose, raffinose oligosaccharide, oligomannose and isomaltooligosaccharide.
7. The prebiotic composition of claim 6 wherein the weight ratio of stachyose to cottonseed oligosaccharide is from 1: 10-10: 1, the weight ratio of stachyose to oligomannose is 11: 1-20: 1 or 1: 20-1: 11, the weight ratio of stachyose to isomaltose hypgather is 1: 10-10: 1.
8. the prebiotic composition of claim 6, further comprising a dietary fiber.
9. Prebiotic composition according to claim 8, characterised in that the dietary fibre is selected from resistant dextrins.
10. Prebiotic composition according to claim 6 or 8, further comprising one or more prebiotics selected from fructo-oligosaccharides, inulin or xylo-oligosaccharides.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810762531.2A CN110710690A (en) | 2018-07-12 | 2018-07-12 | Prebiotic composition for rapid proliferation of beneficial intestinal bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810762531.2A CN110710690A (en) | 2018-07-12 | 2018-07-12 | Prebiotic composition for rapid proliferation of beneficial intestinal bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110710690A true CN110710690A (en) | 2020-01-21 |
Family
ID=69208305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810762531.2A Pending CN110710690A (en) | 2018-07-12 | 2018-07-12 | Prebiotic composition for rapid proliferation of beneficial intestinal bacteria |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110710690A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112931883A (en) * | 2021-03-24 | 2021-06-11 | 浙江屯屯麦生物技术开发有限公司 | Prebiotic composition and preparation method and application thereof |
| CN113331335A (en) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | Prebiotic composition, solid beverage and preparation method of solid beverage |
| CN113576943A (en) * | 2021-07-09 | 2021-11-02 | 中山大学 | Prebiotics fermentation product and preparation method and application thereof |
| CN114128813A (en) * | 2021-12-09 | 2022-03-04 | 天津创源生物技术有限公司 | Beverage for relieving alcoholism and protecting liver and promoting vitality of liver and preparation method thereof |
| CN114832011A (en) * | 2022-05-16 | 2022-08-02 | 武汉自然萃创新科技有限公司 | Prebiotic enema and preparation method and application thereof |
| CN115177632A (en) * | 2022-04-25 | 2022-10-14 | 承葛健康科技(广东)有限公司 | Prebiotic composition with constipation relieving effect |
| CN116210915A (en) * | 2023-02-17 | 2023-06-06 | 山东省农业科学院 | Dietary fiber composition for improving lipid metabolism of obese patients |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102630948A (en) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | High-fiber sugar-free fruit flavored type compound prebiotics and preparation method thereof |
| CN105982009A (en) * | 2015-02-05 | 2016-10-05 | 骆奇 | Composition for regulating human body intestinal micro-ecology |
| WO2017005584A1 (en) * | 2015-07-07 | 2017-01-12 | Alfa Wassermann Spa | Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereof |
| CN107198250A (en) * | 2017-05-23 | 2017-09-26 | 北京瑞千景科技发展有限公司 | Improve intestinal microecology Chronic disease prevention composition and balanced nutritious food and application |
-
2018
- 2018-07-12 CN CN201810762531.2A patent/CN110710690A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102630948A (en) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | High-fiber sugar-free fruit flavored type compound prebiotics and preparation method thereof |
| CN105982009A (en) * | 2015-02-05 | 2016-10-05 | 骆奇 | Composition for regulating human body intestinal micro-ecology |
| WO2017005584A1 (en) * | 2015-07-07 | 2017-01-12 | Alfa Wassermann Spa | Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereof |
| CN107198250A (en) * | 2017-05-23 | 2017-09-26 | 北京瑞千景科技发展有限公司 | Improve intestinal microecology Chronic disease prevention composition and balanced nutritious food and application |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112931883A (en) * | 2021-03-24 | 2021-06-11 | 浙江屯屯麦生物技术开发有限公司 | Prebiotic composition and preparation method and application thereof |
| CN113331335A (en) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | Prebiotic composition, solid beverage and preparation method of solid beverage |
| CN113576943A (en) * | 2021-07-09 | 2021-11-02 | 中山大学 | Prebiotics fermentation product and preparation method and application thereof |
| CN113576943B (en) * | 2021-07-09 | 2022-07-12 | 中山大学 | Prebiotics fermentation product and preparation method and application thereof |
| CN114128813A (en) * | 2021-12-09 | 2022-03-04 | 天津创源生物技术有限公司 | Beverage for relieving alcoholism and protecting liver and promoting vitality of liver and preparation method thereof |
| CN115177632A (en) * | 2022-04-25 | 2022-10-14 | 承葛健康科技(广东)有限公司 | Prebiotic composition with constipation relieving effect |
| CN114832011A (en) * | 2022-05-16 | 2022-08-02 | 武汉自然萃创新科技有限公司 | Prebiotic enema and preparation method and application thereof |
| CN116210915A (en) * | 2023-02-17 | 2023-06-06 | 山东省农业科学院 | Dietary fiber composition for improving lipid metabolism of obese patients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110710690A (en) | Prebiotic composition for rapid proliferation of beneficial intestinal bacteria | |
| Patel et al. | Emerging prospects of macro-and microalgae as prebiotic | |
| Pandey et al. | Probiotics, prebiotics and synbiotics-a review | |
| Sathyabama et al. | Co-encapsulation of probiotics with prebiotics on alginate matrix and its effect on viability in simulated gastric environment | |
| CN110101722B (en) | Application of composite probiotic preparation in preparation of product for treating ulcerative colitis | |
| Ouwehand et al. | Prebiotics and other microbial substrates for gut functionality | |
| Bengmark | Immunonutrition: role of biosurfactants, fiber, and probiotic bacteria | |
| EP3074020B1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children | |
| Liu et al. | Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseases | |
| CN101366734A (en) | Synbiotics medicament composition | |
| CN111109492A (en) | Functional collagen peptide probiotic solid beverage and preparation method thereof | |
| CN108782758B (en) | Fermented synbiotic goat milk powder and preparation method thereof | |
| Kim et al. | Lactobacillus brevis OK56 ameliorates high-fat diet-induced obesity in mice by inhibiting NF-κB activation and gut microbial LPS production | |
| CN113558246A (en) | Symbiotic bifidobacterium composite microcapsule and preparation method thereof | |
| Wang et al. | Interaction between dietary fiber and bifidobacteria in promoting intestinal health | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| Wu et al. | Impact of prebiotics, probiotics, and gut derived metabolites on host immunity | |
| CN110200186B (en) | Probiotic solid beverage and preparation method thereof | |
| BR112021007646A2 (en) | NUTRITIONAL COMPOSITION FOR BABIES FOR USE IN IMPROVING PANCREATIC MATURATION AND INSULIN BIOSYNTHESIS | |
| Takemura et al. | Inulin-type fructans stimulated the growth of exogenously administered Lactobacillus plantarum No. 14 in the mouse gastrointestinal tract | |
| Liu et al. | How do Lycium barbarum polysaccharides promote the adhesion of Lactobacillus to Caco-2 cells? | |
| WO2024008851A1 (en) | Uses of bifidobacterium longum transitional microorganism | |
| CN113397170B (en) | Application of marine prebiotics composition for regulating human intestinal flora | |
| Budhisatria et al. | In vitro and in vivo prebiotic activities of purified oligosaccharides derived from various local bananas (Musa sp.): Tanduk, Uli, Raja Sereh, and Cavendish | |
| Panesar et al. | Probiotics, prebiotics and synbiotics: opportunities, health benefits and industrial challenges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200121 |
|
| WD01 | Invention patent application deemed withdrawn after publication |